Founding offer · lifetime membership for a single £24, exclusive to our first members · closes 20 June Claim your place →
Global Research Partnerships £24 Lifetime Log inCreate free account

Funded Projects › FP7

MINDVIEW · Multimodal Imaging of Neurological Disorders

FP7Status: CLOSED1 September 201331 August 2018EU funding €5,381,872

The key concept behind this proposal is the development of a very high resolution and high efficiency brain dedicated Positron Emission Tomograph (PET) imager that can visualize neurotransmitter pathways and their disruptions in the quest to better diagnose and consequently to better treat schizophrenia. In addition, the plan is for this compact PET imager to be integrated with a Magnetic Resonance Imager Radio Frequency (MRI RF) system to be able to operate as a brain insert in a hybrid imaging setup with practically any MRI scanner.From the technical point of view, we propose to optimize the PET technology for imaging of the human brain with the accuracy typically achieved for small animal brain imaging. To achieve this, we will incorporate the solid state based MRI-compatible PET modules that will be designed to achieve below systemic 1mm spatial resolution in a tomographic reconstruction of the human brain.We aim to achieve the level of PET-MRI compatibility allowing for simultaneous PET and MRI imaging.By combining PET measurements of neurotransmission with fMRI (functional MRI) measurements of Blood Oxygen Level Detection (BOLD) signal changes we will advance to a position where it is possible to learn more about the neurochemical determination of neural activity reflected in BOLD signal changes.The novelty is that both the PET and RF coil systems are integrated into a portable and compact design dedicated to brain examination. This will allow current MR equipment to be easily upgraded into PET/MR systems.To achieve its diagnostic goal, MINDView will be paired with the set of dedicated specific PET imaging agents and endogenous compounds that will be labeled with short-lived positron isotopes. The goal is that dopaminergic, glutamatergic and other pathways will be able to be studied with the new high performance imaging tool. Innovative paradigms such as activation and perturbation and their impact on brain function will be in focus.

Consortium · 10 organisations

coordinator

AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS

ES · €597,487

participant

BENCAR AB

SE · €417,300

participant

NORAS MRI PRODUCTS GMBH

DE · €331,820

participant

GENERAL EQUIPMENT FOR MEDICAL IMAGING SA

ES · €1,949,980

participant

UNIVERSITE DE BRETAGNE OCCIDENTALE

FR · €136,251

participant

UPPSALA UNIVERSITET

SE · €536,000

participant

KAROLINSKA INSTITUTET

SE · €468,784

participant

KLINIKUM RECHTS DER ISAR DER TECHNISCHEN UNIVERSITAT MUNCHEN

DE · €324,200

participant

SENSL TECHNOLOGIES LIMITED

IE · €483,800

participant

UNIVERSITA DEGLI STUDI DI ROMA LA SAPIENZA

IT · €136,250

Research fields

View the official record on CORDIS →

← Find collaborators and more funded projects

Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.